Literature DB >> 12682145

Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5' noncoding region.

Frederick S Nolte1, Alicia M Green, Kristin R Fiebelkorn, Angela M Caliendo, Cynthia Sturchio, Aileen Grunwald, Mimi Healy.   

Abstract

We compared the performance characteristics of a standardized direct sequencing method (TRUGENE HCV 5'NC; Visible Genetics Inc., Toronto, Ontario, Canada) and a reverse hybridization line probe assay (INNO-LiPA HCV II; Bayer Corp., Tarrytown, N.Y.) for genotyping of hepatitis C virus (HCV). Both methods are based on detection of sequence heterogeneity in the 5' noncoding (5'NC) region. Concordance between the genotyping methods was assessed by testing 172 samples representing the six major genotypes. Sequence analysis of the more phylogenetically informative nonstructural 5B (NS5B) region was also done with 148 (86%) samples to confirm the accuracy of and resolve discrepancies between the 5'NC genotyping results. The sensitivities of the methods were assessed by using the 5'NC amplicon from both the qualitative and quantitative AMPLICOR HCV tests (Roche Diagnostics Corp., Indianapolis, Ind.). The ability of the methods to detect mixed-genotype infections was determined with mixtures of two different genotypes at relative concentrations ranging from 1 to 50%. Both 5'NC methods were able to genotype 99.4% of the samples with type agreement for 99.5% and subtype agreement for 68.2% of the samples. No or ambiguous subtype results were found by the line probe assay for 16.5% and by the TRUGENE 5'NC test for 17.1% of the samples. Discrepancies occurred between the line probe assay and NS5B results at the type level for 1.4% of the samples and at the subtype level for 14.2% of the samples. Discrepancies also occurred between the TRUGENE 5'NC and NS5B results at the type level for 2% of the samples and at the subtype level for 8.1% of the samples. We also found two distinct strains of HCV classified as type 2 by analysis of the 5'NC region that were type 1 by analysis of the NS5B region. The sensitivities of the two 5'NC genotyping methods were comparable and dependent on the amplification test used ( approximately 10(3) IU/ml with the qualitative HCV RNA tests and approximately 10(5) IU/ml with the quantitative HCV RNA tests). Genotype mixtures were successfully identified at a relative concentration of 5% by the line probe assay and 10% by the TRUGENE 5'NC test. In conclusion, the performance characteristics of the 5'NC methods were similar and both methods produced accurate results at the genotype level but neither method should be used for subtyping.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682145      PMCID: PMC153875          DOI: 10.1128/JCM.41.4.1558-1564.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  High performance DNA sequencing, and the detection of mutations and polymorphisms, on the Clipper sequencer.

Authors:  T D Yager; L Baron; R Batra; A Bouevitch; D Chan; K Chan; S Darasch; R Gilchrist; A Izmailov; J M Lacroix; K Marchelleta; J Renfrew; J Renfrew; D Rushlow; E Steinbach; C Ton; P Waterhouse; H Zaleski; J M Dunn; J Stevens
Journal:  Electrophoresis       Date:  1999-06       Impact factor: 3.535

2.  Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping.

Authors:  F Ansaldi; F Torre; B M Bruzzone; A Picciotto; P Crovari; G Icardi
Journal:  J Med Virol       Date:  2001-01       Impact factor: 2.327

3.  Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group.

Authors:  D B Smith; J Mellor; L M Jarvis; F Davidson; J Kolberg; M Urdea; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1995-07       Impact factor: 3.891

4.  Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.

Authors:  T Poynard; J McHutchison; Z Goodman; M H Ling; J Albrecht
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

5.  Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; K E Sherman; J J Goedert; A Katsoulidou; A Hatzakis
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

6.  Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections.

Authors:  Y W Hu; E Balaskas; M Furione; P H Yen; G Kessler; V Scalia; L Chui; G Sher
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

7.  Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.

Authors:  S C Lee; A Antony; N Lee; J Leibow; J Q Yang; S Soviero; K Gutekunst; M Rosenstraus
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

8.  Genotyping of hepatitis C virus isolates using CLIP sequencing.

Authors:  R S Ross; S O Viazov; C D Holtzer; A Beyou; A Monnet; C Mazure; M Roggendorf
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

9.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

10.  Simplified hepatitis C virus genotyping by heteroduplex mobility analysis.

Authors:  P A White; X Zhai; I Carter; Y Zhao; W D Rawlinson
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

View more
  31 in total

1.  Comparative evaluation of three commercially available methodologies for hepatitis C virus genotyping.

Authors:  Ted E Schutzbank; Susan E Sefers; Nicole Kahmann; Haijing Li; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 2.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

3.  Multitypic hepatitis C virus infection identified by real-time nucleotide sequencing of minority genotypes.

Authors:  Andrew J Buckton; Siew-Lin Ngui; Catherine Arnold; Katie Boast; Joanne Kovacs; Paul E Klapper; Bharat Patel; Imad Ibrahim; Savita Rangarajan; Mary E Ramsay; Chong-Gee Teo
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States.

Authors:  Jeffrey J Germer; Jayawant N Mandrekar; Jordan L Bendel; P Shawn Mitchell; Joseph D C Yao
Journal:  J Clin Microbiol       Date:  2011-05-25       Impact factor: 5.948

5.  Matrix-assisted laser desorption ionization-time of flight (mass spectrometry) for hepatitis C virus genotyping.

Authors:  Elena N Ilina; Maja V Malakhova; Edward V Generozov; Eugene N Nikolaev; Vadim M Govorun
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

6.  Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions.

Authors:  Elisa Martró; Victoria González; Andrew J Buckton; Verónica Saludes; Gema Fernández; Lurdes Matas; Ramón Planas; Vicenç Ausina
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

7.  Sequencing assays for failed genotyping with the versant hepatitis C virus genotype assay (LiPA), version 2.0.

Authors:  Sylvie Larrat; Jean-Dominique Poveda; Camille Coudret; Katia Fusillier; Nelly Magnat; Anne Signori-Schmuck; Vincent Thibault; Patrice Morand
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

8.  Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice.

Authors:  Stéphane Chevaliez; Magali Bouvier-Alias; Rozenn Brillet; Jean-Michel Pawlotsky
Journal:  PLoS One       Date:  2009-12-08       Impact factor: 3.240

9.  Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4.

Authors:  Jenny Martial; Yoann Morice; Sylvie Abel; André Cabié; Christelle Rat; Frédéric Lombard; André Edouard; Serge Pierre-Louis; Philippe Garsaud; Odile Béra; Roger Chout; Emmanuel Gordien; Paul Deny; Raymond Césaire
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

10.  HCV genotyping using statistical classification approach.

Authors:  Ping Qiu; Xiao-Yan Cai; Wei Ding; Qing Zhang; Ellie D Norris; Jonathan R Greene
Journal:  J Biomed Sci       Date:  2009-07-08       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.